PAX3-FOXO1, the product of the most common chromosomal translocation observed, t(2;13)(q35;q14) (De Giovanni et al., 2009; Shern et al., 2014), drives tumor development by binding to enhancers and super-enhancers to activate an aberrant gene expression signature (Cao et al., 2010; Gryder et al., 2017; Khan et al., 1999). Here, PAX3 is linked to neoplasm.